Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.

Vitale A, Spolverato G, Burra P, De Feo TM, Belli L, Donato F, Baroni GS, Marianelli T, Picciotto A, Toniutto P, Bhoori S, Passigato N, LucĂ  MG, Russo FP, Cillo U, Fagiuoli S; Liver Transplantation NITp working group.

Transpl Int. 2015 Sep;28(9):1055-65. doi: 10.1111/tri.12591. Epub 2015 Apr 30.

2.

High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis.

Papp M, Sipeki N, Vitalis Z, Tornai T, Altorjay I, Tornai I, Udvardy M, Fechner K, Jacobsen S, Teegen B, Sumegi A, Veres G, Lakatos PL, Kappelmayer J, Antal-Szalmas P.

J Hepatol. 2013 Sep;59(3):457-66. doi: 10.1016/j.jhep.2013.04.018. Epub 2013 Apr 29.

PMID:
23639483
3.

Presence of anti-microbial antibodies in liver cirrhosis--a tell-tale sign of compromised immunity?

Papp M, Norman GL, Vitalis Z, Tornai I, Altorjay I, Foldi I, Udvardy M, Shums Z, Dinya T, Orosz P, Lombay B Jr, Par G, Par A, Veres G, Csak T, Osztovits J, Szalay F, Lakatos PL.

PLoS One. 2010 Sep 23;5(9):e12957. doi: 10.1371/journal.pone.0012957.

4.

Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.

De Clercq E.

Med Res Rev. 2009 Jul;29(4):611-45. doi: 10.1002/med.20153. Review.

PMID:
19260077

Supplemental Content

Loading ...
Support Center